Abstract 264P
Background
Lymphomas are the most common testicular malignancy in elderly male with DLBCL being most common subtype. Less common histological subtypes include Burkitt lymphoma and follicular lymphoma. Testicular DLBCL has poor treatment outcomes than nodal DLBCL due to high risk of relapse in opposite testes, CNS and other sites.
Methods
From the database, patients diagnosed as testicular lymphoma over a period of five years from January 2013 to December 2017 at department of Madras Medical College, Chennai were retrieved and analysed.
Results
8 patients were found to have testicular lymphoma with all being DLBCL subtype. Median age of diagnosis was 61 years. 25% (n=2) patients had B symptoms. 4 patients had stage IE, 2 patients had stage II and 2 patients had stage IV. LDH was elevated in stage IV patients. None developed contralateral testicular lymphoma. All patients underwent high inguinal orchidectomy of involved testis. 3 patients had removal of opposite testis after completion of whole treatment and 5 patients received radiotherapy of 30Gy to contralateral testes. All patients received R-CHOP once in 21 days for 6 cycles along with intrathecal methotrexate of 12.5mg except 1 patient receiving 4 cycles only due to poor PS. 2 patients had febrile neutropenia during chemotherapy and got recovered. 2.5 year DFS was 62.5%(n=5) and 2.5 year OS was 75%(n=6) with a median follow up period of 56 months.
Conclusions
Due to rarity of this tumour standard treatment regimen remains unknown. R-CHOP gives treatment outcomes comparable to the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sivasubramaniam.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session